Integra Lifesciences Holdings Corp at Raymond James Institutional Investors Conference (Virtual) Transcript
Okay. Good morning. I think we can get started. Welcome to the third day of the 42nd Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I cover medical devices here at Raymond James. It's really my pleasure to have with us the senior management team from Integra LifeSciences. From the company, we have the company's CFO, Carrie Anderson; and Head of IR, Mike Beaulieu. So we're going to go straight fireside here.
So maybe just to start, though, 2020 was, I think, a tough year for everyone from a growth and a volume perspective. But my sense is that Integra made this a more -- made '20 a more productive year than most. Specifically, I'm thinking of the portfolio changes that enables you to enter '21 with, what I would say is, a more focused, cleaner business mix. Carrie, we always have a broad audience at this conference.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
